Valuation : Sera Prognostics, Inc.

Market Cap 81.66M 70.31M 66.02M 60.26M 113M 7.77B 114M 782M 304M 3.94B 307M 300M 13.05B P/E 2026 *
-3.15x
P/E 2027 * -3.87x
Enterprise Value 81.66M 70.31M 66.02M 60.26M 113M 7.77B 114M 782M 304M 3.94B 307M 300M 13.05B EV / Sales 2026 *
363x
EV / Sales 2027 * 42.4x
Free-Float
85.92%
Yield 2026 *
-
Yield 2027 * -
1 day+2.42%
1 week-2.75%
Current month+3.92%
1 month+3.92%
3 months-3.20%
6 months+0.47%
Current year-28.14%
1 week 1.98
Extreme 1.98
2.21
1 month 1.85
Extreme 1.8514
2.21
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
12.36
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 01/06/2023
Director of Finance/CFO 39 07/06/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 74 20/04/2011
Chairman 58 08/06/2023
Director/Board Member 59 01/11/2011
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 A Free

Director

62,657 0.1641%
7/10/26 A Free

Director

62,697 0.1642%
7/10/26 A Free

Director

61,416 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%-2.75%-36.34%+19.10% 81.66M
-0.73%-0.73%+14.55%+15.40% 22.85B
+0.27%-0.84%+17.82% - 15.03B
+0.13%-0.33%+11.29%-23.49% 3.77B
-0.55%-2.92%+45.00%+36.11% 3.17B
+1.63%+2.07%-21.74%-32.75% 2.1B
-0.73%+2.26%-14.96% - 2.1B
+3.08%+2.96%-16.64%+17.64% 1.57B
+0.88%-1.68%+55.54%+86.24% 1.37B
+2.15%+1.82%-16.32%+3.38% 1.32B
Average +0.73%+1.23%+3.82%+15.20% 5.34B
Weighted average by Cap. -0.37%+0.99%+13.75%+12.72%

Financials

2026 *2027 *
Net sales 225K 194K 182K 166K 312K 21.41M 314K 2.16M 839K 10.86M 845K 826K 35.95M 1.92M 1.66M 1.56M 1.42M 2.67M 183M 2.69M 18.44M 7.18M 92.88M 7.23M 7.07M 308M
Net income -33.93M -29.22M -27.43M -25.04M -47.04M -3.23B -47.38M -325M -126M -1.64B -127M -125M -5.42B -29.1M -25.06M -23.53M -21.48M -40.34M -2.77B -40.63M -279M -108M -1.4B -109M -107M -4.65B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
31/08/26 $2.120 +2.42% 9,522
28/08/26 $2.070 +1.97% 23,119
27/08/26 $2.030 -2.87% 51,436
26/08/26 $2.090 -4.13% 7,282
25/08/26 $2.180 0.00% 17,844
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.070USD
Average target price
5.500USD
Spread / Average Target
+165.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock